A diamidobenzimidazole STING agonist protects against SARS-CoV-2 infection

Coronaviruses are a family of RNA viruses that cause acute and chronic diseases of the upper and lower respiratory tract in humans and other animals. SARS-CoV-2 is a recently emerged coronavirus that has led to a global pandemic causing a severe respiratory disease known as COVID-19 with significant morbidity and mortality worldwide. The development of antiviral therapeutics are urgently needed while vaccine programs roll out worldwide. Here we describe a diamidobenzimidazole compound, diABZI-4, that activates STING and is highly effective in limiting SARS-CoV-2 replication in cells and animals. diABZI-4 inhibited SARS-CoV-2 replication in lung epithelial cells. Administration of diABZI-4 intranasally before or even after virus infection conferred complete protection from severe respiratory disease in K18-ACE2-transgenic mice infected with SARS-CoV-2. Intranasal delivery of diABZI-4 induced a rapid short-lived activation of STING, leading to transient proinflammatory cytokine production and lymphocyte activation in the lung associated with inhibition of viral replication. Our study supports the use of diABZI-4 as a host-directed therapy which mobilizes antiviral defenses for the treatment and prevention of COVID-19. Pharmacological activation of STING protects against SARS-CoV-2 infection.

[1]  Emily M. Lee,et al.  Pharmacological activation of STING blocks SARS-CoV-2 infection , 2021, Science Immunology.

[2]  Wei Liu,et al.  Activation of STING Signaling Pathway Effectively Blocks Human Coronavirus Infection , 2021, Journal of Virology.

[3]  Zhijian J. Chen,et al.  TBK1 recruitment to STING activates both IRF3 and NF-κB that mediate immune defense against tumors and viral infections , 2021, Proceedings of the National Academy of Sciences.

[4]  Shruti Sharma,et al.  cGAS-STING Pathway Does Not Promote Autoimmunity in Murine Models of SLE , 2021, Frontiers in Immunology.

[5]  D. Sachs,et al.  Leveraging the antiviral type I interferon system as a first line of defense against SARS-CoV-2 pathogenicity , 2021, Immunity.

[6]  Xiaoyu Pan,et al.  Inhibition of coronavirus infection by a synthetic STING agonist in primary human airway system , 2021, Antiviral Research.

[7]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[8]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[9]  M. Carcaterra,et al.  Alveolar epithelial cell type II as main target of SARS-CoV-2 virus and COVID-19 development via NF-Kb pathway deregulation: A physio-pathological theory , 2020, Medical Hypotheses.

[10]  Jacques Fellay,et al.  Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 , 2020, Science.

[11]  Shamus P. Keeler,et al.  SARS-CoV-2 infection of hACE2 transgenic mice causes severe lung inflammation and impaired function , 2020, Nature Immunology.

[12]  A. Iwasaki,et al.  Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling , 2020, The Journal of experimental medicine.

[13]  Moriah L. Szpara,et al.  Interferon-independent STING signaling promotes resistance to HSV-1 in vivo , 2020, Nature Communications.

[14]  Nan Yan,et al.  Interferon-Independent Activities of Mammalian STING Mediate Antiviral Response and Tumor Immune Evasion. , 2020, Immunity.

[15]  Jennifer L. Bell,et al.  Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report , 2020, medRxiv.

[16]  Taylor M. Matte,et al.  Human iPSC-derived alveolar and airway epithelial cells can be cultured at air-liquid interface and express SARS-CoV-2 host factors , 2020, bioRxiv.

[17]  Akiko Iwasaki,et al.  Type I and Type III Interferons – Induction, Signaling, Evasion, and Application to Combat COVID-19 , 2020, Cell Host & Microbe.

[18]  Eric Song,et al.  Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling , 2020, bioRxiv.

[19]  L. Dodd,et al.  Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.

[20]  R. Schwartz,et al.  Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 , 2020, Cell.

[21]  M. Letko,et al.  Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses , 2020, Nature Microbiology.

[22]  Wenling Wang,et al.  The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice , 2020, Nature.

[23]  Ralph S. Baric,et al.  Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus , 2020, Journal of Virology.

[24]  Ignacio S. Caballero,et al.  Reconstructed Single-Cell Fate Trajectories Define Lineage Plasticity Windows during Differentiation of Human PSC-Derived Distal Lung Progenitors. , 2020, Cell stem cell.

[25]  D. Kotton,et al.  Derivation of self-renewing lung alveolar epithelial type II cells from human pluripotent stem cells , 2019, Nature Protocols.

[26]  Zhijian J. Chen,et al.  Structural basis of STING binding with and phosphorylation by TBK1 , 2019, Nature.

[27]  Zhijian J. Chen,et al.  Autophagy Induction via STING Trafficking Is a Primordial Function of the cGAS Pathway , 2019, Nature.

[28]  J. Bertin,et al.  Design of amidobenzimidazole STING receptor agonists with systemic activity , 2018, Nature.

[29]  R. Vance,et al.  Tumor‐Derived cGAMP Triggers a STING‐Mediated Interferon Response in Non‐tumor Cells to Activate the NK Cell Response , 2018, Immunity.

[30]  Zhijian J. Chen,et al.  cGAS is essential for the antitumor effect of immune checkpoint blockade , 2017, Proceedings of the National Academy of Sciences.

[31]  J. Nyengaard,et al.  Sensing of HSV-1 by the cGAS–STING pathway in microglia orchestrates antiviral defence in the CNS , 2016, Nature Communications.

[32]  George E. Katibah,et al.  Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. , 2015, Cell reports.

[33]  Ying Wang,et al.  STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. , 2014, Immunity.

[34]  Zhijian J. Chen,et al.  Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway , 2013, Science.

[35]  R. Schreiber,et al.  Type I interferon is selectively required by dendritic cells for immune rejection of tumors , 2011, The Journal of experimental medicine.

[36]  K. Murphy,et al.  Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells , 2011, The Journal of experimental medicine.

[37]  David K. Meyerholz,et al.  Lethal Infection of K18-hACE2 Mice Infected with Severe Acute Respiratory Syndrome Coronavirus , 2006, Journal of Virology.

[38]  Zhijian J. Chen,et al.  Cryo-EM structures of STING reveal its mechanism of activation by cyclic GMP–AMP , 2019, Nature.